|
1
|
Chatzellis E, Alexandraki KI, Androulakis
II and Kaltsas G: Aggressive pituitary tumors. Neuroendocrinology.
101:87–104. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Iglesias P, Magallón R, Mitjavila M,
Rodríguez Berrocal V, Pian H and Díez JJ: Multimodal therapy in
aggressive pituitary tumors. Endocrinol Diabetes Nutr (Engl Ed).
67:469–485. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ilie MD, Jouanneau E and Raverot G:
Aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin
North Am. 49:505–515. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Raverot G, Burman P, McCormack A, Heaney
A, Petersenn S, Popovic V, Trouillas J and Dekkers OM: European
Society of Endocrinology. European society of endocrinology
clinical practice guidelines for the management of aggressive
pituitary tumours and carcinomas. Eur J Endocrinol. 178:G1–G24.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Thakkar K, Sarathi V and Shah NS: Current
Status of diagnosis and management for functioning pituitary
tumors: Part I. Neurol India. 68 (Suppl 1):S13–S19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mehta GU and Lonser RR: Management of
hormone-secreting pituitary adenomas. Neuro Oncol. 19:762–773.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Araujo-Castro M, Berrocal VR and
Pascual-Corrales E: Pituitary tumors: Epidemiology and clinical
presentation spectrum. Hormones (Athens). 19:145–155.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Poiana C, Chirita C, Carsote M, Hortopan D
and Goldstein A: Galactocele and prolactinoma-a pathogenic
association? Maturitas. 6:98–102. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Samperi I, Lithgow K and Karavitaki N:
Hyperprolactinaemia. J Clin Med. 8(2203)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Greenman Y: Prolactinomas and menopause:
Any changes in management? Pituitary. 23:58–64. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tirosh A and Shimon I: Management of
macroprolactinomas. Clin Diabetes Endocrinol. 1(5)2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Iliesiu A, Ungureanu IA, Petca A,
Constantin MM, Petca RC, Sandru F, Constantin T and Dumitrascu MC:
Paraganglioma presenting as a mesenteric cystic mass: A case
report. Exp Ther Med. 20:2489–2492. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nassiri F, Cusimano MD, Scheithauer BW,
Rotondo F, Fazio A, Syro LV, Kovacs K and Lloyd RV: Prolactinomas:
Diagnosis and treatment. Expert Rev Endocrinol Metab. 7:233–241.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Van den Broek MF, van Nesselrooij BP,
Verrijn Stuart AA, van Leeuwaarde RS and Valk GD: Clinical
relevance of genetic analysis in patients with pituitary adenomas:
A systematic review. Front Endocrinol (Lausanne).
10(837)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Barry S and Korbonits M: Update on the
genetics of pituitary tumors. Endocrinol Metab Clin North Am.
49:433–452. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Carty DM, Harte R, Drummond RS, Ward R,
Magid K, Collier D, Owens M and Korbonits M: AIP variant causing
familial prolactinoma. Pituitary. 24:48–52. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Daly AF, Cano DA, Venegas-Moreno E,
Petrossians P, Dios E, Castermans E, Flores-Martínez A, Bours V,
Beckers A and Soto-Moreno A: AIP and MEN1 mutations and AIP
immunohistochemistry in pituitary adenomas in a tertiary referral
center. Endocr Connect. 8:338–348. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Schernthaner-Reiter MH, Trivellin G and
Stratakis CA: Interaction of AIP with protein kinase A
(cAMP-dependent protein kinase). Hum Mol Genet. 27:2604–2613.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cuny T, Barlier A, Feelders R, Weryha G,
Hofland LJ, Ferone D and Gatto F: Medical therapies in pituitary
adenomas: Current rationale for the use and future perspectives.
Ann Endocrinol (Paris). 76:43–58. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Honegger J, Nasi-Kordhishti I, Aboutaha N
and Giese S: Surgery for prolactinomas: A better choice? Pituitary.
23:45–51. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kuo M, Maya MM, Bonert V and Melmed S:
Prospective evaluation of incidental pituitary imaging findings in
the Sella Turcica. J Endocr Soc. 5(bvaa186)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chanson P and Maiter D: The epidemiology,
diagnosis and treatment of Prolactinomas: The old and the new. Best
Pract Res Clin Endocrinol Metab. 33(101290)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lasolle H, Ilie MD and Raverot G:
Aggressive prolactinomas: How to manage? Pituitary. 23:70–77.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Donoho DA and Laws ER Jr: The role of
surgery in the management of prolactinomas. Neurosurg Clin N Am.
30:509–514. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dai C, Liu X, Ma W and Wang R: The
treatment of refractory pituitary adenomas. Front Endocrinol
(Lausanne). 10(334)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hauser BM, Lau A, Gupta S, Bi WL and Dunn
IF: The Epigenomics of pituitary adenoma. Front Endocrinol
(Lausanne). 10(290)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Trouillas J, Delgrange E, Wierinckx A,
Vasiljevic A, Jouanneau E, Burman P and Raverot G: Clinical,
pathological, and molecular factors of aggressiveness in lactotroph
tumours. Neuroendocrinology. 109:70–76. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vroonen L, Daly AF and Beckers A:
Epidemiology and management challenges in prolactinomas.
Neuroendocrinology. 109:20–27. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yoo F, Chan C, Kuan EC, Bergsneider M and
Wang MB: Comparison of male and female prolactinoma patients
requiring surgical intervention. J Neurol Surg B Skull Base.
79:394–400. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Olarescu NC, Perez-Rivas LG, Gatto F, Cuny
T, Tichomirowa MA, Tamagno G and Gahete MD: EYRC (ENEA Young
Researcher Committee). Aggressive and malignant prolactinomas.
Neuroendocrinology. 109:57–69. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Glezer A and Bronstein MD: Prolactinomas.
Endocrinol Metab Clin North Am. 44:71–78. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Langlois F, McCartney S and Fleseriu M:
Recent progress in the medical therapy of pituitary tumors.
Endocrinol Metab (Seoul). 32:162–170. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bettencourt-Silva R, Queirós J, Pereira J
and Carvalho D: Giant prolactinoma, germline BRCA1 mutation, and
depression: A case report. J Med Case Rep. 12(360)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Huynh PP, Ishii LE and Ishii M:
Prolactinomas. JAMA. 325(195)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Giraldi EA and Ioachimescu AG: The role of
dopamine agonists in pituitary adenomas. Endocrinol Metab Clin
North Am. 49:453–474. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Shimon I: Giant prolactinomas.
Neuroendocrinology. 109:51–56. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sahakian N, Castinetti F, Dufour H,
Graillon T, Romanet P, Barlier A, Brue T and Cuny T: Clinical
management of difficult to treat macroprolactinomas. Expert Rev
Endocrinol Metab. 14:179–192. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Vroonen L, Daly AF and Beckers A:
Challenges and controversies in the treatment of prolactinomas.
Expert Rev Endocrinol Metab. 9:593–604. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Salenave S, Ancelle D, Bahougne T, Raverot
G, Kamenický P, Bouligand J, Guiochon-Mantel A, Linglart A, Souchon
PF, Nicolino M, et al: Macroprolactinomas in children and
adolescents: Factors associated with the response to treatment in
77 patients. J Clin Endocrinol Metab. 100:1177–1186.
2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Vermeulen E, D'Haens J, Stadnik T, Unuane
D, Barbe K, Van Velthoven V and Gläsker S: Predictors of dopamine
agonist resistance in prolactinoma patients. BMC Endocr Disord.
20(68)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Maiter D: Management of dopamine
agonist-resistant prolactinoma. Neuroendocrinology. 109:42–50.
2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Espinosa-Cárdenas E, Sánchez-García M,
Ramírez-Rentería C, Mendoza-Zubieta V, Sosa-Eroza E and Mercado M:
High biochemical recurrence rate after withdrawal of cabergoline in
prolactinomas: Is it necessary to restart treatment? Endocrine.
70:143–149. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Vermeulen E, D'Haens J, Stadnik T, Unuane
D, Barbe K, Van Velthoven V and Gläsker S: Predictors of dopamine
agonist resistance in prolactinoma patients. BMC Endocr Disord.
20(68)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lu C, Liu Y, Lu Z and Huan C: Ki-67 and
clinical correlations in patients with resistant prolactinomas. Ann
Clin Lab Sci. 50:199–204. 2020.PubMed/NCBI
|
|
45
|
Stiles CE, Steeds RP and Drake WM:
Monitoring patients receiving dopamine agonist therapy for
hyperprolactinaemia. Ann Endocrinol (Paris). 82:182–186.
2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Souteiro P, Belo S and Carvalho D:
Dopamine agonists in prolactinomas: When to withdraw? Pituitary.
23:38–44. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Castinetti F: Radiation techniques in
aggressive pituitary tumours and carcinomas. Rev Endocr Metab
Disord. 21:287–292. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pérez Pinzón J, González-Devia D, Kattah
Calderón W, López Panqueva RDP and Jiménez Hakim E: Unusual course
of an aggressive pituitary prolactinoma: Case report and review of
the literature. Case Rep Neurol. 11:148–156. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Barkhoudarian G, Palejwala SK, Ogunbameru
R, Wei H, Eisenberg A and Kelly DF: Early recognition and
initiation of temozolomide chemotherapy for refractory, invasive
pituitary macroprolactinoma with long-term sustained remission.
World Neurosurg. 118:118–124. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Chen C, Yin S, Zhang S, Wang M, Hu Y, Zhou
P and Jiang S: Treatment of aggressive prolactinoma with
temozolomide: A case report and review of literature up to date.
Medicine (Baltimore). 96(e8733)2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lizzul L, Lombardi G, Barbot M, Ceccato F,
Gardiman MP, Regazzo D, Bellu L, Mazza E, Losa M and Scaroni C:
Long-course temozolomide in aggressive pituitary adenoma: Real-life
experience in two tertiary care centers and review of the
literature. Pituitary. 23:359–366. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Elbelt U, Schlaffer SM, Buchfelder M,
Knappe UJ, Vila G, Micko A, Deutschbein T, Unger N, Lammert A,
Topuzoglu-Müller T, et al: Efficacy of temozolomide therapy in
patients with aggressive pituitary adenomas and carcinomas-a German
survey. J Clin Endocrinol Metab. 105(dgz211)2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Almalki MH, Aljoaib NN, Alotaibi MJ,
Aldabas BS, Wahedi TS, Ahmad MM and Alshahrani F: Temozolomide
therapy for resistant prolactin-secreting pituitary adenomas and
carcinomas: A systematic review. Hormones (Athens). 16:139–149.
2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Aydoğan Bİ, Ünlütürk U, Emral R and Güllü
S: Course of aggressive somatotroph, corticotroph and mammotroph
tumors under temozolomide; Report of three cases and review of the
literature. Turk Neurosurg: May 7, 2017 (Epub ahead of print).
|
|
55
|
Mele C, Mencarelli M, Caputo M, Mai S,
Pagano L, Aimaretti G, Scacchi M, Falchetti A and Marzullo P:
Phenotypes associated with MEN1 syndrome: A focus on
genotype-phenotype correlations. Front Endocrinol (Lausanne).
11(591501)2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Miulescu R, Balaban DV, Sandru F and Jinga
M: Cutaneous manifestations in pancreatic diseases-A review. J Clin
Med. 9(2611)2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Ortiz LD, Syro LV, Scheithauer BW, Rotondo
F, Uribe H, Fadul CE, Horvath E and Kovacs K: Temozolomide in
aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo).
67 (Suppl 1):S119–S123. 2012.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Duhamel C, Ilie MD, Salle H, Nassouri AS,
Gaillard S, Deluche E, Assaker R, Mortier L, Cortet C and Raverot
G: Immunotherapy in corticotroph and lactotroph aggressive tumors
and carcinomas: Two case reports and a review of the literature. J
Pers Med. 10(88)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Cooper O, Bonert VS, Rudnick J, Pressman
BD, Lo J, Salvatori R, Yuen KCJ, Fleseriu M and Melmed S:
EGFR/ErbB2-targeting lapatinib therapy for aggressive
prolactinomas. J Clin Endocrinol Metab. 106:e917–e925.
2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Souteiro P and Karavitaki N: Dopamine
agonist resistant prolactinomas: Any alternative medical treatment?
Pituitary. 23:27–37. 2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Raverot G, Vasiljevic A, Jouanneau E and
Lasolle H: Confirmation of a new therapeutic option for aggressive
or dopamine agonist-resistant prolactin pituitary neuroendocrine
tumors. Eur J Endocrinol. 181:C1–C3. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Gomes-Porras M, Cárdenas-Salas J and
Álvarez-Escolá C: Somatostatin analogs in clinical practice: A
review. Int J Mol Sci. 21(1682)2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Lv L, Jiang Y, Yin S, Hu Y, Chen C, Ma W,
Jiang S and Zhou P: Mammosomatotroph and mixed
somatotroph-lactotroph adenoma in acromegaly: A retrospective study
with long-term follow-up. Endocrine. 66:310–318. 2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Coopmans EC, van Meyel SWF, Pieterman KJ,
van Ipenburg JA, Hofland LJ, Donga E, Daly AF, Beckers A, van der
Lely AJ and Neggers SJCMM: Excellent response to pasireotide
therapy in an aggressive and dopamine-resistant prolactinoma. Eur J
Endocrinol. 181:K21–K27. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Siddiqui M, Vora A, Ali S, Abramowitz J
and Mirfakhraee S: Pasireotide: A novel treatment for tumor-induced
hypoglycemia due to insulinoma and non-islet cell tumor
hypoglycemia. J Endocr Soc. 5(bvaa171)2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Zhao N, Yang X, Li C, Ma J and Yin X:
Efficacy and safety of pasireotide for Cushing's disease: A
protocol for systematic review and meta-analysis. Medicine
(Baltimore). 99(e23824)2020.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Lasolle H, Vasiljevic A, Borson-Chazot F
and Raverot G: Pasireotide: A potential therapeutic alternative for
resistant prolactinoma. Ann Endocrinol (Paris). 80:84–88.
2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Oki Y: Medical management of functioning
pituitary adenoma: An update. Neurol Med Chir (Tokyo). 54:958–965.
2014.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Valea A, Ghervan C, Carsote M, Morar A,
Iacob I, Tomesc F, Pop DD and Georgescu C: Effects of combination
therapy: Somatostatin analogues and dopamine agonists on GH and
IGF1 levels in acromegaly. Clujul Med. 88:310–313. 2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Valea A, Carsote M, Ghervan C and
Georgescu C: Glycemic profile in patients with acromegaly treated
with somatostatin analogue. J Med Life. 8:82–86. 2015.PubMed/NCBI
|
|
71
|
Zhang D, Way JS, Zhang X, Sergey M,
Bergsneider M, Wang MB, Yong WH and Heaney AP: Effect of everolimus
in treatment of aggressive prolactin-secreting pituitary adenomas.
J Clin Endocrinol Metab. 104:1929–1936. 2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Zhang J, Francois R, Iyer R, Seshadri M,
Zajac-Kaye M and Hochwald SN: Current understanding of the
molecular biology of pancreatic neuroendocrine tumors. J Natl
Cancer Inst. 105:1005–1017. 2013.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Wolin EM: The expanding role of
somatostatin analogs in the management of neuroendocrine tumors.
Gastrointest Cancer Res. 5:161–168. 2012.PubMed/NCBI
|
|
74
|
Chen R, Duan J, Li L, Ma Q, Sun Q, Ma J,
Li C, Zhou X, Chen H, Jing Y, et al: mTOR promotes pituitary tumor
development through activation of PTTG1. Oncogene. 36:979–988.
2017.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Gorshtein A, Rubinfeld H, Kendler E,
Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M and
Shimon I: Mammalian target of rapamycin inhibitors rapamycin and
RAD001 (everolimus) induce anti-proliferative effects in
GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer.
16:1017–1027. 2009.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao
Y, Feng M, Bao X, Li G, Wang J, et al: Inhibition of PI3K/AKT/mTOR
pathway enhances temozolomide-induced cytotoxicity in pituitary
adenoma cell lines in vitro and xenografted pituitary adenoma in
female nude mice. Endocrinology. 154:1247–1259. 2013.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Whitelaw BC: How and when to use
temozolomide to treat aggressive pituitary tumours. Endocr Relat
Cancer. 26:R545–R552. 2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Schreck KC and Grossman SA: Role of
temozolomide in the treatment of cancers involving the central
nervous system. Oncology (Williston Park). 32:555–560.
2018.PubMed/NCBI
|
|
79
|
Arora A and Somasundaram K: Glioblastoma
vs temozolomide: Can the red queen race be won? Cancer Biol Ther.
20:1083–1090. 2019.PubMed/NCBI View Article : Google Scholar
|
